Study to Assess the Pharmacokinetics and Safety of AZD9977 in Participants With Renal Impairment
Status:
Recruiting
Trial end date:
2021-12-15
Target enrollment:
Participant gender:
Summary
This is a single dose, non-randomized, open-label, parallel group study. The study will be
conducted in participants with severe renal impairment and compared with matched participants
with normal renal function. The duration of the study for an individual participant from
Screening to Follow-up will be approximately 5 weeks.